LYNAVOY (Linerixibat) Patent Expiration, LOE Window & CMS Spending
LYNAVOY (Linerixibat) by Intercept: FDA Orange Book core substance LOE 2031-09-06 (last listed 2033-03-17), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $12,083 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Intercept |
| FDA Application & Pathway | N220295 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2031-09-06 |
| Last Listed Patent or Exclusivity Date | 2033-03-17 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($12,083 intro WAC) |